A new drug, recombinant ADAMTS13 (rADAMTS13), has recently gained FDA approval for the prophylactic and on-demand management of congenital TTP [77,78] in adults and children, replacing the defective ADAMTS13 protein. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.